Nonlinear pharmacokinetics of (±)3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") and its major metabolites in squirrel monkeys at plasma concentrations of MDMA that develop after typical psychoactive doses

Journal of Pharmacology and Experimental Therapeutics

Volumn 327, Issue 1, 2008, Pages 38-44

  Mueller, Melanie ^a,b   Peters, Frank T ^b   Maurer, Hans H ^b   McCann, Una D ^a   Ricaurte, George A ^a,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SAARLAND UNIVERSITY   (Germany)

^c DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DIHYDROXYMETHAMPHETAMINE; 3,4 METHYLENEDIOXYAMPHETAMINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4 HYDROXY 3 METHOXYMETHAMPHETAMINE; DRUG METABOLITE; SEROTONIN; UNCLASSIFIED DRUG; 4-HYDROXY-3-METHOXYMETHAMPHETAMINE; ALPHA METHYLEPININE; ALPHA-METHYLEPININE; DRUG DERIVATIVE; EPININE; METHAMPHETAMINE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BRAIN; DISEASE SEVERITY; DOSE RESPONSE; DRUG ABUSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NEUROTOXICITY; NONHUMAN; NONLINEAR SYSTEM; PRIORITY JOURNAL; SQUIRREL MONKEY; ANIMAL; CEBIDAE; HALF LIFE TIME; SPECIES DIFFERENCE;

ANIMALS; AREA UNDER CURVE; DEOXYEPINEPHRINE; HALF-LIFE; MALE; METHAMPHETAMINE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; SAIMIRI; SPECIES SPECIFICITY;

EID: 52649087879     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.108.141366     Document Type: Article

References (28)

1. Cho AR and Kumangai Y (1994) Metabolism of amphetamine and other arylisopropylamines. In: Amphetamine and its Analogs (Cho AK, Segal DS eds), pp 43-77, Academic Press, San Diego, CA.
2. Chu T, Kumagai Y, DiStefano EW, and Cho AK (1996) Disposition of methylenedioxymethamphetamine and three metabolites in the brains of different rat strains and their possible roles in acute serotonin depletion. Biochem Pharmacol 51:789-796.
3. de la Torre R, Farré M, Ortuño J, Mas M, Brenneisen R, Roset PN, Segura J, and Camí J (2000) Non-linear pharmacokinetics of MDMA ('ecstasy') in humans. Br J Clin Pharmacol 49:104-109.
4. de la Torre R, Farré M, Roset PN, Pizarro N, Abanades S, Segura M, Segura J, and Camí J (2004) Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. Ther Drug Monit 26:137-144.
5. Dumont GJ and Verkes RJ (2006) A review of acute effects of 3,4-methylenedioxymethamphetamine in healthy volunteers. J Psychopharmacol 20:176-187.
6. Easton N and Marsden CA (2006) Ecstasy: are animal data consistent between species and can they translate to humans? J Psychopharmacol 20:194-210.
7. Erives GV, Lau SS, and Monks TJ (2008) Accumulation of neurotoxic thioether metabolites of 3,4-(+/-)-methylenedioxymethamphetamine in rat brain. J Pharmacol Exp Ther 324:284-291.
8. Green AR, Mechan AO, Elliott JM, O'Shea E, and Colado MI (2003) The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacol Rev 55:463-508.
9. Helmlin HJ, Bracher K, Bourquin D, Vonlanthen D, and Brenneisen R (1996) Analysis of 3,4-methylenedioxyme-thamphetamine (MDMA) and its metabolites in plasma and urine by HPLC-DAD and GC-MS. J Anal Toxicol 20:432-440.
10. Heydari A, Yeo KR, Lennard MS, Ellis SW, Tucker GT, and Rostami-Hodjegan A (2004) The mechanism-based inactivation of CYP2D6 by methylenedioxymethamphetamine (MDMA). Drug Metab Dispos 32:1213-1217.
11. Ingelman-Sundberg M, Sim SC, Gomez A, and Rodriguez-Antona C (2007) Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 116:496-526.
12. Kolbrich EA, Goodwin RS, Gorelick DA, Hayes RJ, Stein EA, and Huestis MA (2008) Plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine after controlled oral administration to young adults. Ther Drug Monit 30:320-332.
13. Kreth K, Kovar K, Schwab M, and Zanger UM (2000) Identification of the human cytochromes P450 involved in the oxidative metabolism of "Ecstasy"-related designer drugs. Biochem Pharmacol 59:1563-1571.
14. Mahmood I (1999) Allometric issues in drug development. J Pharm Sci 88:1101-1106.
15. Mahmood I and Balian JD (1996) Interspecies scaling: a comparative study for the prediction of clearance and volume using two or more than two species. Life Sci 59:579-585.
16. Maurer HH, Bickeboeller-Friedrich J, Kraemer T, and Peters FT (2000). Toxicokinetics and analytical toxicology of amphetamine-derived designer drugs ('Ecstasy'). Toxicol Lett 112-113:133-142.
17. Mechan A, Yuan J, Hatzidimitriou G, Irvine RJ, McCann UD, and Ricaurte GA (2006) Pharmacokinetic profile of single and repeated oral doses of MDMA in squirrel monkeys: relationship to lasting effects on brain serotonin neurons. Neuropsychopharmacology 31:339-350.
18. Monks TJ, Jones DC, Bai F, and Lau SS (2004) The role of metabolism in 3,4-(+)-methylenedioxyamphetamine and 3,4-(+)-methylenedioxymethamphetamine (ecstasy) toxicity. Ther Drug Monit 26:132-136.
19. Mordenti J and Chappell W (1989) The use of interspecies scaling in toxicokinetics. In: Toxicokinetics and new drug development (Yacobi A, Kelly J, Batra V eds), pp 42-96, Pergamon Press, New York.
20. Mueller M, Peters FT, Ricaurte GA, and Maurer HH (2007) Validated liquid chromatographic-electrospray ionization mass spectrometric assay for simultaneous determination of 3,4-methylenedioxymethamphetamine and its metabolites 3,4-methylenedioxyamphetamine, 3,4-dihydroxymethamphetamine, and 4-hydroxy-3-methoxymethamphetamine in squirrel monkey plasma. J Chromatogr B Analyt Technol Biomed Life Sci 855:262-270.
21. Pacifici R, Zuccaro P, Hernandez López C, Pichini S, Di Carlo S, Farré M, Roset PN, Ortuño J, Segura J, and Torre RL (2001) Acute effects of 3,4-methylenedioxymethamphetamine alone and in combination with ethanol on the immune system in humans. J Pharmacol Exp Ther 296:207-215.
22. Peters FT, Samyn N, Wahl M, Kraemer T, De Boeck G, and Maurer HH (2003) Concentrations and ratios of amphetamine, methamphetamine, MDA, MDMA, and MDEA enantiomers determined in plasma samples from clinical toxicology and driving under the influence of drugs cases by GC- NICI-MS. J Anal Toxicol 27:552-559.
23. Quinton MS and Yamamoto BK (2006) Causes and consequences of methamphetamine and MDMA toxicity. AAPS J 8:E337-E347.
24. Ramamoorthy Y, Yu AM, Suh N, Haining RL, Tyndale RF, and Sellers EM (2002) Reduced (+/-)-3,4-methylenedioxymethamphetamine ("Ecstasy") metabolism with cytochrome P450 2D6 inhibitors and pharmacogenetic variants in vitro. Biochem Pharmacol 63:2111-2119.
25. Segura M, Farré M, Pichini S, Peiró AM, Roset PN, Ramírez A, Ortuño J, Pacifici R, Zuccaro P, Segura J, et al. (2005) Contribution of cytochrome P450 2D6 to 3,4-methylenedioxymethamphetamine disposition in humans: use of paroxetine as a metabolic inhibitor probe. Clin Pharmacokinet 44:649-660.
26. Tucker GT, Lennard MS, Ellis SW, Woods HF, Cho AK, Lin LY, Hiratsuka A, Schmitz DA, and Chu TY (1994) The demethylenation of methylenedioxymethamphetamine ("ecstasy") by debrisoquine hydroxylase (CYP2D6). Biochem Pharmacol 47:1151-1156.
27. Van LM, Hargreaves JA, Lennard MS, Tucker GT, and Rostami-Hodjegan A (2007) Inactivation of CYP2D6 by methylenedioxymethamphetamine in different recombinant expression systems. Eur J Pharm Sci 32:8-16.
28. Yang J, Jamei M, Heydari A, Yeo KR, de la Torre R, Farré M, Tucker GT, and Rostami-Hodjegan A (2006) Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA. J Psychopharmacol 20:842-849.